Table 3.
Men with LQT1 |
Women with LQT1 |
|||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Mutation location (vs nonmissense mutations) | ||||
Cytoplasmic loop (S2–S3/S4–S5 linkers) | 1.21 (0.72–2.04 | 0.48 | 2.62 (1.59–4.26) | <.001 |
MS | 1.02 (0.63–1.97) | 0.54 | 1.01 (0.62–1.89) | .56 |
N/C terminus | 0.89 (0.52–1.91) | 0.87 | 1.14 (0.51–2.37) | .43 |
QTc duration (ms) | ||||
500–550 vs <500 | 1.70 (0.63–4.57) | 0.29 | 6.85 (2.74–17.10) | <.001 |
>550 vs < 500 | 3.11 (1.19–8.15) | 0.02 | 5.93 (1.89–18.62) | .002 |
Time-dependent syncope | ||||
Syncope vs no syncope | 4.06 (2.22–7.41) | <0.001 | 2.43 (1.43–4.85) | .002 |
ACA = aborted cardiac arrest; CI = confidence interval; HR = hazard ratio; LQT1 = long QT syndrome type 1; QTc = corrected QT interval; SCD = sudden cardiac death; MS = membrane spanning.
Findings were further adjusted for missing QTc values, time-dependent beta-blocker therapy.
Models were carried out in the total population by using interaction-term analysis, with interactions tested one at a time; cytoplasmic loop-by-sex interaction = .07; all other interaction P values were >.10.